These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 31227053)

  • 41. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
    Umbricht CA; Benešová M; Schibli R; Müller C
    Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lutetium
    Emmett L; Willowson K; Violet J; Shin J; Blanksby A; Lee J
    J Med Radiat Sci; 2017 Mar; 64(1):52-60. PubMed ID: 28303694
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
    Benešová M; Umbricht CA; Schibli R; Müller C
    Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Current use of PSMA-PET in prostate cancer management.
    Maurer T; Eiber M; Schwaiger M; Gschwend JE
    Nat Rev Urol; 2016 Apr; 13(4):226-35. PubMed ID: 26902337
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The
    Scarpa L; Buxbaum S; Kendler D; Fink K; Bektic J; Gruber L; Decristoforo C; Uprimny C; Lukas P; Horninger W; Virgolini I
    Eur J Nucl Med Mol Imaging; 2017 May; 44(5):788-800. PubMed ID: 28083690
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prostate-specific membrane antigen radioligand therapy of prostate cancer.
    Beheshti M; Heinzel A; von Mallek D; Filss C; Mottaghy FM
    Q J Nucl Med Mol Imaging; 2019 Mar; 63(1):29-36. PubMed ID: 30644306
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synthesis and Evaluation of
    Li Z; Jiang Y; Ruan Q; Yin G; Han P; Duan X; Zhang J
    Mol Pharm; 2024 Oct; 21(10):5305-5314. PubMed ID: 39298677
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
    Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
    J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
    [TBL] [Abstract][Full Text] [Related]  

  • 49.
    Fendler WP; Rahbar K; Herrmann K; Kratochwil C; Eiber M
    J Nucl Med; 2017 Aug; 58(8):1196-1200. PubMed ID: 28663195
    [No Abstract]   [Full Text] [Related]  

  • 50. Synthesis and evaluation of a novel urea-based
    Zha Z; Ploessl K; Choi SR; Wu Z; Zhu L; Kung HF
    Nucl Med Biol; 2018 Apr; 59():36-47. PubMed ID: 29459281
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
    Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
    BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In Vitro and In Vivo Characterization of an
    Lütje S; Franssen GM; Herrmann K; Boerman OC; Rijpkema M; Gotthardt M; Heskamp S
    J Nucl Med; 2019 Jul; 60(7):1017-1022. PubMed ID: 30655329
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Evolving Role of Prostate-Specific Membrane Antigen-Based Diagnostics and Therapeutics in Prostate Cancer.
    Dorff TB; Fanti S; Farolfi A; Reiter RE; Sadun TY; Sartor O
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():321-330. PubMed ID: 31099673
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PSMA PET and Radionuclide Therapy in Prostate Cancer.
    Bouchelouche K; Turkbey B; Choyke PL
    Semin Nucl Med; 2016 Nov; 46(6):522-535. PubMed ID: 27825432
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prospects of medium specific activity (177) Lu in targeted therapy of prostate cancer using (177) Lu-labeled PSMA inhibitor.
    Chakraborty S; Chakravarty R; Shetty P; Vimalnath KV; Sen IB; Dash A
    J Labelled Comp Radiopharm; 2016 Jul; 59(9):364-71. PubMed ID: 27264278
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives.
    Zschaeck S; Lohaus F; Beck M; Habl G; Kroeze S; Zamboglou C; Koerber SA; Debus J; Hölscher T; Wust P; Ganswindt U; Baur ADJ; Zöphel K; Cihoric N; Guckenberger M; Combs SE; Grosu AL; Ghadjar P; Belka C
    Radiat Oncol; 2018 May; 13(1):90. PubMed ID: 29751842
    [No Abstract]   [Full Text] [Related]  

  • 57. Prostate-specific membrane antigen-guided salvage lymph node dissection in recurrent prostate cancer: a novel technology to detect lymph node metastases.
    Maurer T; Gschwend JE; Eiber M
    Curr Opin Urol; 2018 Mar; 28(2):191-196. PubMed ID: 29028767
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls.
    Hofman MS; Hicks RJ; Maurer T; Eiber M
    Radiographics; 2018; 38(1):200-217. PubMed ID: 29320333
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.
    Weineisen M; Schottelius M; Simecek J; Baum RP; Yildiz A; Beykan S; Kulkarni HR; Lassmann M; Klette I; Eiber M; Schwaiger M; Wester HJ
    J Nucl Med; 2015 Aug; 56(8):1169-76. PubMed ID: 26089548
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013.
    Kulkarni HR; Singh A; Schuchardt C; Niepsch K; Sayeg M; Leshch Y; Wester HJ; Baum RP
    J Nucl Med; 2016 Oct; 57(Suppl 3):97S-104S. PubMed ID: 27694180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.